GSK’s Seroxat pay-for-delay deals may restrict competition: AG
23-01-2020
GSK to widen access to medicines in world’s poorest countries
01-04-2016
360b / Shutterstock.com
GSK has been fined more than £37 million ($53 million) by the UK government for “anti-competitive conduct” in relation to ‘pay for delay’ deals centring on anti-depressant drug Seroxat (paroxetine).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
GSK, anti-competition, generic, Seroxat, patent, patent infringement, pay-for-delay, GUK, Alpharma, paroxetine, Competition and Markets Authority
